Quantification of Transcriptome Responses of the Rumen Epithelium to Butyrate Infusion using RNA-seq Technology

Ransom L. Baldwin Vi1, Sitao Wu2, Weizhong Li2, Congjun Li1, Brian J. Bequette3 and Robert W. Li1
1USDA-ARS, Bovine Functional Genomics Laboratory, Beltsville, MD, USA. 2Center for Research in Biological Systems, University of California, San Diego, CA, USA. 3Department of Animal and Avian Sciences, University of Maryland, College Park, MD, USA. Corresponding author email: ransom.baldwin@ars.usda.gov; robert.li@ars.usda.gov

Abstract: Short-chain fatty acids (SCFAs), such as butyrate, produced by gut microorganisms, play a critical role in energy metabolism and physiology of ruminants as well as in human health. In this study, the temporal effect of elevated butyrate concentrations on the transcriptome of the rumen epithelium was quantified via serial biopsy sampling using RNA-seq technology. The mean number of genes transcribed in the rumen epithelial transcriptome was 17,323.63 ± 277.20 (±SD; N = 24) while the core transcriptome consisted of 15,025 genes. Collectively, 80 genes were identified as being significantly impacted by butyrate infusion across all time points sampled. Maximal transcriptional effect of butyrate on the rumen epithelium was observed at the 72-h infusion when the abundance of 58 genes was altered. The initial reaction of the rumen epithelium to elevated exogenous butyrate may represent a stress response as Gene Ontology (GO) terms identified were predominantly related to responses to bacteria and biotic stimuli. An algorithm for the reconstruction of accurate cellular networks (ARACNE) inferred regulatory gene networks with 113,738 direct interactions in the butyrate-epithelium interactome using a combined cutoff of an error tolerance ($\epsilon = 0.10$) and a stringent $P$-value threshold of mutual information ($5.0 \times 10^{-11}$). Several regulatory networks were controlled by transcription factors, such as CREBBP and TTF2, which were regulated by butyrate. Our findings provide insight into the regulation of butyrate transport and metabolism in the rumen epithelium, which will guide our future efforts in exploiting potential beneficial effect of butyrate in animal well-being and human health.

Keywords: butyrate, epithelial, networks, RNA-seq, ruminant, transcriptome
Introduction
Short-chain fatty acids (SCFAs, also known as volatile fatty acids or VFAs) are produced in the gastrointestinal tract by microbial fermentation of carbohydrate substrates of both exogenous (dietary fiber) and endogenous origin (mucus). SCFAs contribute up to 75% of the total energy requirement in ruminants and ~10% for humans. A broad range of biological functions have been ascribed to SCFAs, specifically butyrate, in addition to their value in energy and nutritional metabolism. While as a preferred energy source for ruminal epithelial cells, butyrate plays a critical role in the development of the rumen epithelium. As an indirect factor, butyrate is able to affect blood flow in the gastrointestinal (GI) tract as well as insulin and glucagon secretion. Furthermore, butyrate reinforces intestinal barriers and modulates motility and visceral sensitivity of the intestine. Butyrate modulates cell differentiation and motility, induces apoptosis, and inhibits cell proliferation in vitro in contrast to the observed effects on cell proliferation documented in vivo. Butyrate is known to be anti-inflammatory and anti-tumorigenic. Recently, butyrate has been shown to reduce bacterial translocation and internalization resulting from metabolic stress in human colon-derived cells. Beneficial effects of butyrate on human health and animal well-being have been extensively reviewed.

Steady-state butyrate concentration in the rumen represents a balance between butyrate biosynthesis by ruminal microorganisms and absorption and utilization by the rumen epithelium. Among factors that affect butyrate output of the gut microbial ecosystem, such as redox potential and pH, gut turnover and motility, and mucosal transport, substrates in the gut play an essential role in butyrate production, possibly due to their influence on microbial population composition and dynamics. The community-level response of rumen microorganisms to exogenous butyrate has recently been characterized. Dietary supplements, such as butyrogenic resistant starch, and probiotic administration of butyrate-producing bacteria have been exploited in human medicine to boost gut butyrate concentration for its potential health benefit. In ruminants, butyrate produced by gut microbes is rapidly removed by the rumen or gut epithelium, and subsequently metabolized to ketone bodies (acetoacetate and β-hydroxybutyrate) or oxidized to CO₂ prior to being released into circulation such that only 25% of the butyrate enters the systemic circulation. While substantial amounts of butyrate are absorbed across the rumen epithelium via passive diffusion, either trans- or para-cellularly, other forms of butyrate transport may exist. Indeed, a butyrate transporter, SLC5A8, has been identified. Much of our knowledge relating to the transcriptional effects of butyrate is derived from in vitro studies. However, butyrate has long been known to have an opposite effect in vivo, especially on cell proliferation. In the present study, we quantified the changes in the rumen epithelial transcriptome of dairy cows in response to butyrate infusion using RNA-seq technology and bioinformatic tools.

Materials and Methods
Animal experiment
Four ruminally-cannulated Holstein cows used in this study were previously described. Briefly, the cows in their mid-lactation were fed ad libitum standard lactation rations with 50% corn silage and 50% concentrate on a dry matter basis. All animal care and handling were conducted according to the guidelines approved by the USDA Beltsville Area Institutional Animal Care (Protocol # 09-008). Cows were moved to a tie stall barn for adaptation and acclimation 7 days prior to the experiment. Ruminal infusion of butyrate was initiated immediately following 0h sampling (baseline controls) and thereafter continued for 168 h at a rate of 5.0 L/day of a 2.5 M solution (representing ~10% of daily anticipated metabolizable energy intake to support lactation) in a buffered saliva solution (pH 7.0; 3.8% KHCO₃, 7.3% NaHCO₃) as a continuous infusion. Following the 168 h infusion, infusion was stopped and cows were maintained on the basal lactation ration for an additional 168 h for sampling. Rumen epithelial samples were serially collected via biopsy through rumen fistulae at 0, 24, 72, and 168 h of infusion, and 24 and 168 h post infusion (post 24 h and post 168 h, respectively). Ruminal pH was monitored using a standard pH meter and recorded at every sampling. Rumen epithelial samples were saved in RNAlater and stored in −80°C until RNA extraction. Additionally, a bovine epithelial cell line treated with 10 mM of sodium butyrate (N = 4) and PBS, respectively, for 24 h was used as an in vitro model for comparison.
RNA extraction and sequencing using RNA-seq

Total RNA from 24 rumen epithelial samples and 8 cell line samples was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) followed by DNase digestion and Qiagen RNeasy column purification (Qiagen, Valencia, CA, USA) as previously described. The RNA integrity was verified using an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA). High-quality RNA (RNA Integrity number or RIN > 9.0) was processed using an Illumina TruSeq RNA sample prep kit following the manufacturer’s instruction (Illumina, San Diego, CA, USA). After quality control procedures, individual RNA-seq libraries were pooled based on their respective sample-specific 6-bp adaptors and sequenced at 50 bp/sequence read using an Illumina HiSeq 2000 sequencer as described previously. Approximately 25.7 million sequences per sample (Mean $\pm$ SD = 25,746,641 ± 7,637,237.4) were generated.

Data analysis and bioinformatics

Raw sequence reads were first checked using our quality control pipeline. Nucleotides of each raw sequence read were scanned for low quality and trimmed using SolexaQA. Trimming removed ~24.9% of the raw reads; and mean length of resultant input reads were 48.96 bp ($\pm$0.46, SD). Input reads were then aligned to the bovine reference genome (UMD3.1) using TopHat. Approximately 96.68% of input reads were aligned to the bovine genome whereas 71.58% of input reads were uniquely mapped to the gene space in the bovine genome. Each SAM output file from TopHat alignment, along with the GTF file from ENSEMBL bovine genebuild v65.0, were used in the Cuffdiff program in the Cufflink package (v1.3.0) as input files to test for differential gene expression. Mapped reads were normalized based on upper-quartile normalization method. Cuffdiff models the variance in fragment counts across replicates using the negative binomial distribution as described.

Differentially expressed genes in the transcriptome identified were further analyzed using Gene Ontology (GO) analysis (https://github.com/tanghaibao/goatools). Enrichment of certain GO terms was determined based on Fisher’s exact test. A multiple correction control (permutation to control false discovery rate, FDR) was implemented to set up the threshold to obtain the lists of significantly over-represented GO terms.

Co-regulatory gene networks were analyzed using Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNE). Raw mapped sequence reads from 32 samples, including 24 rumen epithelial samples and 8 samples from a bovine epithelial cell line were first normalized (per million mapped reads) and log2 transformed. Only 15,469 genes with mean mapped reads greater than 10.0 across all 32 samples were used for subsequent analysis. Relative expression values of these genes were used as input files to infer global regulatory networks.

Results

A snapshot of the rumen epithelial transcriptome

Collectively, a total of 20,371 genes were detected at least once in at least one of the 24 rumen epithelial samples. The number of genes expressed per sample was 17,323.63 ± 277.20 (Mean ± SD). The number of genes with mean hits ≥ 5.0 were 15,015 whereas the core transcriptome of the rumen epithelium consisted of 15,025 genes, ie, genes represented by at least one sequence hit in each of the 24 samples tested.

According to the transcript abundance classification described previously, approximately 70.78% of genes transcribed in the rumen epithelium can be classified into “very rare” with a relative abundance ≤15 molecules per cell (Table 1), followed by “not expressed” (0 molecule per cell) at 17.24% and “rare” (16–99 molecules per cell) at 10.41%. “Moderately abundant” genes accounted for 1.32% while the abundant transcripts with ≥500 molecules per cell accounted for only 0.25% of genes detected in the transcriptome. Unlike what was observed in the bovine muscle tissue where the transcriptome was dominated by a handful of

| Transcript category | Rumen epithelium | Small intestine |
|---------------------|-----------------|-----------------|
| Not expressed       | 17.24%          | 15.23%          |
| Very rare           | 70.78%          | 68.27%          |
| Rare                | 10.41%          | 14.91%          |
| Moderately abundant | 1.32%           | 1.41%           |
| Abundant            | 0.25%           | 0.18%           |
Genes significantly impacted by butyrate

A total of 80 genes were found to be affected in the rumen epithelium by butyrate infusion at ≥ one time point at a stringent cutoff, FDR < 5% (Table 2). Compared to pre-infusion at 0h, 24 h infusion affected 15 genes, including down-regulation of solute carrier family 5 (iodide transporter), member 8 (SLC5A8), leukocyte surface antigen (CD47), lipopolysaccharide binding protein (LBP), immunoglobulin lambda-like polypeptide 1 (IGLL1), and lactoperoxidase (LPO). The maximal effect of butyrate was observed at 72 h infusion when 59 genes were influenced, including lymphocyte antigen 6D (LY6D), keratin 75 (KRT75), and tubulin beta-3 chain (TBB3). While the impact on some genes, such as a novel protein (ENSBTAG00000000390), which was strongly induced by butyrate at only the 24 h infusion sampling, was seemingly transient, transcriptional responses of butyrate on many genes were long-lasting. The ruminal butyrate concentration returned to its pre-infusion basal level 168 h after the infusion withdrawal (Fig. 1). However, as many as 13 genes remained significantly affected at 168 h post-infusion, compared to 0h, and these included cadherin 26 (CDH26), desmoglein 1 (DSG1), and kallikrein-related peptidase 10 (KLK10). 53 of the 80 differentially expressed genes were also significantly impacted by butyrate in the in vitro model. However, the remaining 27 genes were only significantly regulated by butyrate in the rumen epithelium, such as dual oxidase maturation factors 1 and 2 (DUOXA1 and DUOXA2) and keratin 36 and keratin 75 (KRT 36 and KRT75). Additionally, of the 80 genes affected by butyrate, a majority were down-regulated by butyrate treatment, which is consistent with the effect of butyrate observed in bovine epithelial cells in vitro (Wu et al 2012, personal communication). Eight genes up-regulated by butyrate at ≥one time point were heat shock 70 kDa protein 6 (HSPA6, 24 h), transglutaminase 2 (TGM2, 72 h and 168 h), alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C, 72 h and post 168 h), small nucleolar RNA SNORA31 (SNORA31, 168 h), farnesyl pyrophosphate synthase (FPFS, post 124 h), keratin 36 (KRT36, post 168 h), ornithine decarboxylase (ODC, post 168 h), and peptidoglycan recognition protein 2 (PGLYRP2, post 168 h).

Gene Ontology (GO) analysis

GO terms significantly enriched in the rumen epithelium in response to butyrate infusion were identified using GOATool. At 24 h infusion, five biological processes were significantly enriched at a Bonferroni-corrected $P \times 10^{-5}$ (Table 3A), including responses to bacteria and biotic stimuli. When all 80 genes significantly impacted by butyrate at one or more time points were analyzed, biological processes such as responses to bacteria and other organisms were enriched, consistent with the 24 h observation. In contrast, cellular components related to “organelle” were significantly depleted by butyrate infusion when assessed relative to all 15,015 genes expressed in the rumen epithelium with mean mapped reads ≥5.0 (Table 3B).

Regulatory gene networks

Using a combined stringent cutoff of an error tolerance $\epsilon = 0.10$ and a $P$-value threshold of mutual information (MI) at $5.0 \times 10^{-5}$, ARACNE inferred global gene networks with 113,738 direct interactions in the butyrate-epithelium interactome. Top 67 genes controlling >5% of all direct interactions and can be considered as hubs or master regulators (Supplementary File 1). Among these genes, 46 were impacted by butyrate in in vivo and/or in vitro models. Of the 46, 7 were known transcription factors or translation regulators, including CREB.
binding protein (CREBBP), eukaryotic translation termination factor 1 (ETF1), hypoxia inducible factor 1, alpha (HIF1A), lysine (K)-specific demethylase 5A (KDM5A), regulatory factor X, 2 (RFX2), transcription elongation factor A (TCEA3), and transcription termination factor, RNA polymerase II (TTF2). The master regulator with the greatest number of direct interactions (or the first neighbors) was ETF1 (ENSBTAG00000011415). The product of this gene acts as an omnipotent protein release factor (RF) and directs the termination of nascent peptide synthesis (translation) in response to termination codons. ETF1 was down-regulated by butyrate in vitro \( (P \text{ value } = 3.97 \times 10^{-8}, \text{ FDR} = 1.00 \times 10^{-5}) \). ARACNE inferred 123 direct interactions (1st neighbors) and 6,195 2nd neighbors for ETF1. Among the indirect interactions (2nd neighbors), 1052 of the 1472 genes involved were significantly impacted by butyrate, including a total of 111 transcription factors in vitro. The predominant GO terms identified as enriched among its 1st neighbors relate to the cellular component organelle (GO:0043226), including membrane-bounded organelle (GO:0043227) and intracellular organelle (GO:0043229). CREBBP (ENSBTAG00000026403) encodes a protein with intrinsic histone acetyltransferase activity, which acetylates both histone and non-histone proteins. CREBBP acts as a transcriptional coactivator of RNA polymerase II-mediated transcription and is known to play a critical role in cell growth and human diseases. This gene was significantly down-regulated by butyrate infusion and had 87 1st neighbors (Fig. 2). An additional 189 genes were involved in 3,327 of indirect interactions of CREBBP (2nd neighbors). Of these CREBBP 2nd neighbors, 140 were regulated by butyrate including 19 transcription factors. Not coincidently, the GO terms predominantly enriched in the direct interaction of CREBBP were related to biological processes such as histone modification (GO:0016570) and covalent chromatin modification (GO0016569), cellular components such as histone acetyltransferase complex (GO:0000123) and NuA4 histone acetyltransferase complex (GO:0035267), and molecular functions such as histone acetyltransferase activity (GO:0004402) and nucleic acid binding (GO:0003676).

**Discussion**

Multiple effects of butyrate on local (intestinal) and systemic physiological function are presumably due to its actions as a potent regulator of gene expression.\(^4\)\(^6\) Butyrate metabolism, both biosynthesis by gut microorganisms and utilization in the gut, is tightly regulated and thus, imbalance could play a critical role in the pathology of humans and animals. Typically, increased production of SCFA, especially butyrate, results in lower luminal pH, which, in turn, creates favorable niche for and stimulates proliferation of butyrate-producing bacteria.\(^12\) In modern intensive production systems used for ruminants, especially during physiologically critical stages, such as weaning and the transition or periparturient period in dairy cattle, high concentrate rations are fed which can result in abrupt increases in SCFA production. This circumstance often results in production in excess of the utilization capacity, subsequently leading to the development of ruminal acidosis, a prominent digestive disorder with a significant economical impact.\(^27\)\(^28\) Individual variation in the capacity for uptake of acetate and butyrate among animals fed the same rations can explain the degree of acidosis observed.\(^29\) In fact, considerable effort has focused on development of practical nutritional intervention strategies for use during transition periods to enhance rumen epithelial surface area prior to the introduction of high VFA producing rations to facilitate better absorptive capacity and mitigate negative effects of acidosis.\(^30\) To date, these strategies have yielded mixed results with respect to increasing papillae surface area and total absorptive capacity (Andersen, personal communication). The development of a better understanding of the regulation of both rumen epithelial growth promotion and VFA transport capacity remains a concern to the industry.\(^39\) In this study, we assessed the rumen epithelial transcriptome dynamics when butyrate concentration was elevated due to direct ruminal infusion with buffered butyric acid in order to assess transcriptional effects of butyrate and its potential role in regulating butyrate transport in cattle.

The majority of our knowledge on regulatory impact of butyrate on global gene expression is derived from in vitro studies and observations.\(^6\)\(^31\)\(^32\) However, caution in interpretation of in vitro data and application of knowledge gained in vitro to in vivo models is warranted. SCFAs, such as butyrate, are known to promote rumen development and stimulate the proliferation of rumen epithelial cells in vivo.\(^33\) However, butyrate inhibits the proliferation
Table 2. Genes significantly impacted by butyrate in the rumen epithelium detected by RNA-seq technology.

| Gene_id       | Symbol     | Gene name                          | Locus                                      | 24 h | 72 h  | 168 h | Post 24 h | Post 168 h |
|---------------|------------|------------------------------------|--------------------------------------------|------|-------|--------|-----------|-----------|
| ENSBTAG00000001100 | IL22RA1    | Interleukin 22 receptor, alpha 1    | 2:129351697–129378160                      | 0.57 | 0.37**| 0.41   | 0.83      | 0.92      |
| ENSBTAG00000001497 | MRAS       | Muscle RAS oncogene homolog         | 1:131765942–131834001                      | 0.96 | 0.76  | 0.86   | 0.81      | 0.64***   |
| ENSBTAG00000002088 | TMX2       | Uncharacterized protein             | 11:46575177–46584984                       | 0.51***| 0.93  | 0.97   | 0.96      | 1.25      |
| ENSBTAG00000002404 | TBC1D16    | Thioredoxin-related transmembrane protein 2 | 15:82363843–82372527                      | 0.87 | 0.73**| 0.82***| 0.98      | 0.95      |
| ENSBTAG00000003192 | CD47       | CD47 molecule                       | 15:82363843–82372527                      | 0.77***| 0.73***| 0.89   | 1.06      | 1.21      |
| ENSBTAG00000003948 | FPPS       | Farnesyl pyrophosphate synthase     | 3:15356046–15374937                       | 1.01 | 0.85  | 0.88   | 1.27**    | 1.46***   |
| ENSBTAG00000004208 | PLEKHG6    | Pleckstrin homology family member 6 | 5:104415804–104431128                      | 0.73 | 0.36**| 0.41*  | 0.72      | 0.82      |
| ENSBTAG00000004256 | ODC        | Ornithine decarboxylase             | 11:87178097–87182503                      | 0.74 | 0.56  | 0.65   | 1.29      | 2.96**    |
| ENSBTAG00000004322 | FOS        | FBJ murine osteosarcoma viral oncogene homolog | 10:86883738–86887169                   | 0.80 | 0.43**| 0.55   | 0.89      | 0.75      |
| ENSBTAG00000004884 | SLC4A5     | Solute carrier family 4, member 5   | 11:10283281–10403977                      | 0.57 | 0.39**| 0.48   | 0.58      | 0.67      |
| ENSBTAG00000004971 | GRAM        | GRAM domain containing 1C           | 1:58963949–59063256                       | 0.68***| 0.68***| 0.82** | 1.13      | 0.72***   |
| ENSBTAG00000005397 | CD46       | Membrane cofactor protein           | 16:77483016–77522665                      | 0.82 | 0.74**| 0.85   | 0.88      | 0.81      |
| ENSBTAG00000005466 | C8orf58    | Chromosome 8 open reading frame 58  | 8:70406943–70412090                       | 0.74 | 0.70**| 0.84   | 0.75      | 0.75      |
| ENSBTAG00000005580 | SZT2       | Seizure threshold 2 homolog (mouse) | 3:103160271–103201060                      | 0.91 | 0.79* | 0.95   | 0.92      | 0.92      |
| ENSBTAG00000006464 | ADP-Ribosylation factor-binding protein GGA1 | 5:109960752–109979896                  | 0.91 | 0.70***| 0.82***| 0.86   | 0.87      |           |
| ENSBTAG00000006984 | CD55       | CD55 molecule, decay accelerating factor for complement | 16:5105576–5124229                       | 0.84 | 0.68**| 0.84   | 0.95      | 1.08      |
| ENSBTAG00000007399 | LAMP2      | Lysosomal-associated membrane protein 2 | X:4846777–4879916                       | 0.88 | 0.78* | 0.82   | 0.83      | 0.80      |
| ENSBTAG00000008442 | NSF        | N-ethylmaleimide-sensitive factor    | 19:46081985–46228565                      | 0.74 | 0.57**| 0.73   | 0.78      | 0.82      |
| ENSBTAG00000008700 | CRCT1      | Cysteine-rich C-terminal 1          | 3:18222997–18224799                       | 0.55 | 0.40* | 0.39*  | 0.91      | 0.68      |
| ENSBTAG00000009575 | C6orf170   | Chromosome 6 open reading frame 170 | 9:30195128–30400435                      | 0.86 | 0.76  | 0.75   | 0.68*     | 0.69      |
| ENSBTAG00000009995 | CPEB4      | Cytoplasmic polyadenylation element binding protein | 20:5512160–5584540                      | 0.75 | 0.67* | 0.79   | 0.84      | 0.75      |
| Gene Accession | Gene Name | Description | Chromosome | Start | End | Log2 Fold Change | p-Value | Adjusted p-Value | q-Value |
|---------------|-----------|-------------|------------|-------|-----|-----------------|---------|-----------------|--------|
| ENSBTAG00000010670 | VSIG8 | V-set and immunoglobulin domain containing 8 | 3 | 3942946 | 9950485 | 0.58 | 0.27*** | 0.34*** | 0.62 | 0.72 |
| ENSBTAG00000011482 | SLC43A2 | Solute carrier family 43, member 2 | 19 | 23261579 | 23301008 | 0.80 | 0.47* | 0.49** | 0.62 | 0.82 |
| ENSBTAG00000011525 | SLC5A8 | Solute carrier family 5 (iodide transporter), member 8 | 5 | 65387536 | 65453818 | 0.32* | 0.33* | 0.38 | 0.90 | 1.49 |
| ENSBTAG000000012280 | PGLYRP2 | Peptidoglycan recognition protein 2 | 7 | 8702089 | 8707156 | 1.09 | 0.64 | 0.82 | 2.27 | 7.00*** |
| ENSBTAG000000012780 | LPO | Lactoperoxidase | 19 | 9441748 | 9471498 | 0.37*** | 0.72 | 0.76 | 1.14 | 0.72 |
| ENSBTAG000000013205 | Interleukin 1 receptor accessory protein | 17 | 17798340 | 0.61 | 0.46** | 0.66 | 0.89 | 1.41 |
| ENSBTAG000000013507 | SPRR3 | Small proline-rich protein 3 | 3 | 2269407 | 32284496 | 0.23*** | 0.61 | 0.62 | 0.88 | 0.73 |
| ENSBTAG000000013578 | DSG1 | Desmoglein 1 | 24 | 26089488 | 26133405 | 0.64 | 0.26*** | 0.21*** | 0.35** | 0.34** |
| ENSBTAG000000013999 | FAM20B | Family with sequence similarity 20, member B | 16 | 61810680 | 61852109 | 0.82 | 0.68*** | 0.83 | 0.90 | 0.80 |
| ENSBTAG000000014289 | ZFYVE9 | Zinc finger, FYVE domain containing 9 | 3 | 94600423 | 94713143 | 0.79 | 0.67* | 0.75 | 0.80 | 0.79 |
| ENSBTAG000000014367 | PRKX | Protein kinase, X-linked | 13 | 13875323 | 13874777 | 0.87 | 0.70*** | 0.86 | 0.88 | 0.87 |
| ENSBTAG000000014945 | IQSEC2 | IQ motif and Sec7 domain 2 | 9 | 96082196 | 96158317 | 0.82 | 0.60*** | 0.76 | 0.80 | 0.83 |
| ENSBTAG000000014984 | RPRD2 | Regulation of nuclear pre-mRNA domain containing 2 | 3 | 20254978 | 20345588 | 0.93 | 0.80 | 0.93 | 0.84 | 0.72* |
| ENSBTAG000000015129 | KLK10 | Kallikrein-related peptidase 10 | 18 | 57448224 | 57454197 | 0.58 | 0.45* | 0.36** | 0.68 | 0.35** |
| ENSBTAG000000015796 | DNAJC5 | DnaJ (Hsp40) homolog, subfamily C, member 5 | 13 | 54382946 | 54408528 | 0.85 | 0.66*** | 0.78 | 0.96 | 1.05 |
| ENSBTAG000000015915 | SBSN | Suprabasin | 18 | 46358552 | 46363200 | 0.66 | 0.24*** | 0.16*** | 0.32* | 0.40 |
| ENSBTAG000000016121 | KRT75 | Keratin 75 | 5 | 27630614 | 27640849 | 0.81 | 0.45* | 0.47 | 0.59 | 0.77 |
| ENSBTAG000000016208 | TGM2 | Transglutaminase 2 | 13 | 67663137 | 67697607 | 1.40 | 2.05* | 2.23* | 0.94 | 1.62 |
| ENSBTAG000000016239 | DUOXA2 | Dual oxidase maturation factor 2 | 10 | 65525529 | 65540482 | 0.50 | 0.48* | 0.55 | 1.11 | 1.22 |
| ENSBTAG000000016242 | DUOXA1 | Dual oxidase maturation factor 1 | 10 | 65525529 | 65540482 | 0.50 | 0.48* | 0.55 | 1.11 | 1.22 |
| ENSBTAG000000016864 | LBP | Lipopolysaccharide binding protein | 13 | 67874743 | 67910095 | 0.47* | 0.54 | 0.63 | 0.86 | 0.92 |
| ENSBTAG000000016968 | CHST4 | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 4 | 18 | 39665072 | 39671884 | 0.38* | 0.39* | 0.55 | 0.94 | 0.71 |
| ENSBTAG000000018252 | ARRDC4 | Arrestin domain containing 4 | 21 | 8924762 | 8939028 | 0.49* | 0.46** | 0.41** | 0.96 | 0.87 |
| ENSBTAG000000018937 | Heme oxygenase (decycling) 2 | 25 | 3621446 | 3649596 | 0.88 | 0.72*** | 0.81* | 0.90 | 0.94 |
| ENSBTAG000000019107 | GAS7 | Growth arrest-specific 7 | 19 | 29670743 | 29876650 | 0.96 | 0.69* | 0.87 | 0.86 | 0.81 |

(Continued)
| Gene_id       | Symbol | Gene name                                      | Locus                      | 24 h | 72 h | 168 h | Post 24 h | Post 168 h |
|--------------|--------|-----------------------------------------------|----------------------------|------|------|-------|-----------|------------|
| ENSBTAG00000019822 | TPPP3  | Tubulin polymerization-promoting protein family member 3 | 18:35121242–35124820 | 1.73 | 0.29 | 0.20* | 0.69      | 0.71       |
| ENSBTAG00000019876 | DSC1   | Desmocollin 1                                 | 24:26283414–26321590      | 1.07 | 0.78 | 0.66* | 0.63      | 0.76       |
| ENSBTAG000000020261 | CDH26  | Cadherin 26                                    | 13:57057696–57091107      | 0.21 | 0.20 | 0.16  | 0.20      | 0.13*      |
| ENSBTAG000000230384 | WDR47  | WD repeat domain 47                           | 3:3446313–34508600        | 0.82 | 0.57**| 0.62**| 0.75      | 0.75       |
| ENSBTAG000000230262 | SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | 24:12747968–12765314 | 1.10 | 0.44**| 0.43**| 0.64      | 0.99       |
| ENSBTAG00000023730  | TBB3   | Tubulin beta-3 chain                          | 18:14761259–14769914      | 0.79 | 0.49* | 0.51  | 0.69      | 0.81       |
| ENSBTAG00000025531  | PSORS1C2 | Psoriasis susceptibility 1 candidate 2         | 23:27793272–27794712      | 0.50 | 0.49* | 0.63  | 1.19      | 0.97       |
| ENSBTAG00000026585  | Elongin A | Elongin A                                     | 2:129738382–129752889     | 0.87 | 0.70* | 0.81  | 1.00      | 1.01       |
| ENSBTAG000000272225 | LAP    | Lingual antimicrobial peptide                 | 27:5124122–5125987        | 0.35**| 0.36***| 0.38**| 0.55      | 0.76       |
| ENSBTAG00000030301  | MAP7D1 | MAP7 domain containing 1                      | 3:110233981–110243621     | 0.70 | 0.48* | 0.62  | 0.83      | 1.00       |
| ENSBTAG00000030484  | KLK12  | Kallikrein-related peptidase 12               | 18:57461616–57465567      | 0.53 | 0.47  | 0.29**| 0.60      | 0.24**     |
| ENSBTAG00000031160  | IGLL1  | Immunoglobulin lambda-like polypeptide 1      | 17:72826679–73152862      | 0.61**| 0.80  | 1.10  | 1.12      | 0.77       |
| ENSBTAG00000031551  | PRSS53 | Protease, serine, 53                          | 25:27450355–27455369      | 0.46* | 0.40***| 0.38**| 0.67      | 0.76       |
| ENSBTAG00000033107  | OSMR   | Oncostatin M receptor                          | 20:35521409–35588186      | 0.71 | 0.56**| 0.69  | 0.93      | 1.08       |
| ENSBTAG00000033398  | HKDC1  | Hexokinase domain containing 1                | 28:25752420–25791456      | 0.63 | 0.31**| 0.30**| 0.48      | 0.77       |
| ENSBTAG00000033669  | IL17RC | Interleukin 17 receptor C                      | 22:16873473–16885025      | 0.91 | 0.70* | 0.80  | 0.96      | 1.16       |
| ENSBTAG00000034189  | ADH1C  | Alcohol dehydrogenase 1C (class I), gamma polypeptide | 6:26656287–26672428 | 0.86 | 4.57* | 3.46  | 0.94      | 5.55***    |
| ENSBTAG00000034498  | LY6D   | Lymphocyte antigen 6D                         | 14:2801382–2803020        | 0.56 | 0.19* | 0.37  | 0.34      | 0.52       |
| ENSBTAG00000035171  | SERPINB5 | Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | 24:62319471–62329373 | 0.89 | 0.69  | 0.52  | 0.30**    | 0.43       |
| ENSBTAG00000035171  | SERPINB5 | Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | 24:62319471–62329373 | 0.89 | 0.69  | 0.52  | 0.30**    | 0.43       |
| ENSBTAG00000038540  | Aox4   | Aldehyde oxidase 4                            | 26:25060218–25073503      | 0.97 | 0.66* | 0.72  | 0.80      | 0.81       |
| ENSBTAG00000038878  | Uncharacterized protein | Aldehyde oxidase 4 | 2:89699123–8971871 | 0.68 | 0.46  | 0.32**| 0.16***   | 0.44       |
| ENSBTAG00000039035  | Uncharacterized protein | Spire homolog 2 (Drosophila) | 3:8027844–8029776 | 13.40***| 0.98  | 1.10  | 2.05      | 0.85       |
| ENSBTAG00000040356  | SPIRE2 | Spire homolog 2                               | 18:14694451–14723123      | 0.78 | 0.65**| 0.80  | 0.90      | 0.90       |
| ENSBTAG00000040394  | PRSS27 | Protease, serine 27                           | 25:2126943–2133828        | 0.46* | 0.50  | 0.50  | 0.62      | 0.63       |
| ENSBTAG00000040507  | ARHGEF18 | Rho/Rac guanine nucleotide exchange factor (GEF) 18 | 7:17513880–17565624 | 0.74 | 0.58* | 0.75  | 0.94      | 0.90       |
| ENSBTAG00000043553  | GPX3   | Glutathione peroxidase 3 (plasma)             | 7:64286947–64295116       | 0.51 | 0.49* | 0.52  | 0.71      | 0.67       |
Rumen epithelial transcriptomics

| Gene ID          | Gene Name         | Chromosome | Start | End   | Log2 Fold Change | FDR   | Significance |
|------------------|-------------------|------------|-------|-------|------------------|-------|--------------|
| ENSBTAG00000044673 | SnORA31          | 4:15035753–15183208 | 0.98  | 2.70** | 4.41*            | 0.99  | 2.17         |
| ENSBTAG00000046124 | KRT36            | 19:42325913–42329903 | 0.91  | 2.96  | 2.14            | 0.98  | 1.10         |
| ENSBTAG00000046482 | Uncharacterized protein | 10:26113953–26114424 | 0.35* | 0.34* | 0.52            | 0.69  | 0.70         |
| ENSBTAG00000046917 | GPR22            | 4:48576431–48851596 | 0.50* | 0.50* | 0.52            | 0.83  | 1.00         |

Notes: Fold changes (treated/control at 0 h, N = 4). *FDR < 1%, **FDR < 0.1%, ***FDR < 0.05%.

Butyrate also induces apoptosis and differentiation of tumor cells. Moreover, an in vitro study of epithelial cells of different origin (rat small intestine vs. human colon) has demonstrated that the cell type affects butyrate uptake characteristics. In fact, opposite effects of butyrate are observed for many cellular processes, such as cell proliferation and division, between in vitro and in vivo models and are clearly reflected in transcriptome characteristics.

A number of genes related to cell proliferation and cell cycle progress were significantly down-regulated by a 24-h 10 mM butyrate incubation of established bovine rumen epithelial cells in long-term culturing (Wu et al 2012, personal communication). In contrast, expression of these same genes in the rumen epithelium in the present data set was not altered despite a 2-fold increase from 19.5 mM to 38.5 mM in intraruminal butyrate concentration (Fig. 1). Interestingly, the abundance of a butyrate transporter, SLC5A8, in the rumen epithelial transcriptome was significantly reduced concomitant with intraruminal butyrate concentration increases. However, SLC5A8 expression at the mRNA level was significantly increased ∼21 fold by butyrate exposure in vitro (Fig. 3). This apparent opposite effect of butyrate on the expression of its transporter is suggestive of alternative regulatory mechanisms relating to butyrate uptake control and transport by the intact rumen epithelium and cells in culture. Moreover, cellular butyrate metabolism may be different between in vivo and in vitro models due to changes in the rate of removal of end product as well as changes between cell-cell interactions and micro-environments present in vivo, but disrupted in vitro. To this point, epithelial metabolism of butyrate, especially the pathways leading to ketogenesis, helps to maintain a butyrate concentration gradient in vivo, which in turn facilitates butyrate uptake and affects butyrate intracellular concentrations.

Rate-limiting enzymes in the ruminal ketogenic process, such as acetyl-CoA acetyl transferase (ACAT) and 3-hydroxy-3-methylglutaryl CoA synthases (HMGCS) 1 (cytoplasmic) and 2 (mitochondrial), play an important role in regulating butyrate metabolism at the substrate level. As depicted in Table 4, key enzymes in butyrate metabolic pathways exhibited a different expression pattern between the cell line
Figure 1. Ruminal concentrations (mM) of short-chain fatty acids in response to butyrate infusion. Notes: 0 h = baseline, immediately prior to initiation of continuous infusion with butyrate. 24 h, 72 h, and 168 h = 24, 72, and 168 h after continuous infusion, respectively. Post 24 h and post 168 h = 24 h and 168 h after infusion withdrawal, respectively. Red: acetate; Blue: butyrate; Green: propionate. Error bars = standard deviation, N = 4.

and the rumen epithelium. As expected, HMGCS2 of mitochondrial origin was significantly up-regulated by butyrate in vitro, in response to increased butyrate concentration. However, expression of HMGCS2 remained unchanged in vivo.

Table 3. Gene Ontology (GO) terms significantly impacted in the rumen epithelium by butyrate. (A) At 24 h infusion. (B) Collectively in all time points.

| GO_id           | Status | GO description                          | Ratio | P_unadjusted | P_bonferroni | FDR   |
|-----------------|--------|-----------------------------------------|-------|--------------|--------------|-------|
| (A)             |        |                                         |       |              |              |       |
| GO:0009617      | E      | Response to bacterium                    | 4/67  | 4.85E-07     | 1.72E-04     | 0.000 |
| GO:0051707      | E      | Response to other organism               | 4/137 | 8.52E-06     | 3.02E-03     | 0.010 |
| GO:0042742      | E      | Defense response to bacterium            | 3/56  | 2.19E-05     | 7.77E-03     | 0.027 |
| GO:0051704      | E      | Multi-organism process                   | 4/208 | 4.41E-05     | 1.56E-02     | 0.039 |
| GO:0009607      | E      | Response to biotic stimulus              | 4/219 | 5.39E-05     | 1.91E-02     | 0.043 |
| GO:0050729      | E      | Positive regulation of inflammatory response | 2/25  | 0.000278     | 9.85E-02     | 0.122 |
| (B)             |        |                                         |       |              |              |       |
| GO:0043231      | P      | Intracellular membrane-bounded organelle | 8/4872| 3.47E-06     | 0.0029       | 0.003 |
| GO:0043227      | P      | Membrane-bounded organelle               | 9/4877| 1.89E-05     | 0.0158       | 0.012 |
| GO:0043229      | P      | Intracellular organelle                  | 12/5577| 2.07E-05     | 0.0174       | 0.013 |
| GO:0009617      | E      | Response to bacterium                    | 5/68  | 3.03E-05     | 0.0254       | 0.055 |
| GO:0043226      | P      | Organelle                                | 13/5583| 6.13E-05     | 0.0514       | 0.074 |
| GO:0004252      | E      | Serine-type endopeptidase activity       | 5/81  | 7.06E-05     | 0.0593       | 0.078 |
| GO:0051707      | E      | Response to other organism               | 6/140 | 1.01E-04     | 0.0845       | 0.154 |

Notes: *Ratio = the number of significantly regulated genes that can be assigned to this GO term/all genes assigned to this GO term [among 15,015 genes expressed in the rumen epithelium with a mean hit count $\geq 5.0$. Under the status, “E” (enriched) = GO term is significantly higher in the study group than those in the population while “P” (depleted) = GO terms significantly lower in the study group than in the population. The number of permutation = 1000. The biological interpretation of high-throughput expression data generated using microarrays or RNA-seq technology requires both differential expression and differential network analyses. Many transcriptional regulators exert their impact on biological functions via post-transcriptional mechanisms with subtle or no apparent changes at mRNA expression level detectable by tools for assessing differential expression alone. However, differential network analysis relies on powerful computational tools to extract accurate regulatory gene networks reflecting causal interactions underlying biological processes or phenotypes. Of several algorithms available, those based on information theory, including estimating mutual information values, such as ARACNE, perform well in inferring global gene networks, especially for smaller sample sizes. ARACNE is based on the assumptions that the expression level of a given gene is a random variable and the mutual relationships between them can be derived by statistical dependences. Our results provided further support for the utility of this approach in constructing regulatory gene networks that depict phenotypes and regulation of biological processes. An example from this current study is the regulatory network controlled by FBJ murine osteosarcoma viral oncogene homolog, or c-fos (FOS), which was significantly down-regulated.
Figure 2. A regulatory gene network controlled by CREB binding protein (CREBBP).
Notes: The network was inferred using ARACNE at a combined stringent cutoff of an error tolerance $\varepsilon = 0.10$ and a $P$-value threshold of mutual information (MI) at $5.0 \times 10^{-11}$. CREBBP had 87 direct interactions (the first neighbors) and 4139 indirect interactions (the second neighbors, not shown). The expression of the CREBBP gene, a transcription factor, at the mRNA level was significantly regulated by butyrate. The color cycle with gene symbols represented genes significantly regulated by butyrate.

Figure 3. Relative expression of a butyrate transporter, solute carrier family 5 (iodide transporter), member 8 (SLC5A8).
Notes: The number denotes the relative abundance of the transcript in both the bovine epithelial cell and in the bovine rumen epithelium. cT: control, cells treated with PBS; BT: cells treated with 10 mM butyrate for 24 h in vitro. *False discovery rate (FDR) $< 0.05$; ***FDR $< 0.001$. 

Gene Regulation and Systems Biology 2012:6
by butyrate in both in vitro and in vivo models. As a transcription factor, FOS dimerizes with another oncogene JUN to form the AP-1 complex, which regulates transcription of a diverse range of genes and is implicated in many biological processes including cell proliferation and differentiation as well as tumor transformation and progression. In the current data set, ARACNE inferred a network of four direct interactions (1st neighbors) for FOS and 32 indirect interactions (Fig. 4). All four direct interactions, cingulin (CGN), heparin-binding epidermal growth factor-like growth factor (HBEGF), intermediate filament family orphan 2 (IFFO2), and jun proto-oncogene (JUN), were up-regulated by butyrate (at both $P < 10^{-6}$ and FDR $< 10^{-5}$). Moreover, of 24 genes in the 2nd neighbors category, all were also regulated by butyrate, including three transcription factors, JUN, upstream transcription factor 2, c-fos interacting (USF2), and REST corepressor 1 (RCOR1). GO analysis identified GO terms significantly enriched in this network, including SMAD binding (GO:0046332 and GO:0070412), SMAD protein signal transduction (GO:0060395), and transforming growth factor (TGF)-β receptor signaling (GO:0007179). FOS binding at the TGF-β1 promoter proximal AP-1 site is required for TGF-β1 production by colon carcinoma cells. Indeed, previous studies have shown that SMAD proteins cooperate with FOS/JUN complex to mediate TGF-β1-induced transcription. Thus, ARACNE correctly inferred a direct interaction between FOS and JUN (Fig. 4) as well as interaction between JOS and

### Table 4. Expression levels of key enzymes involved in butyrate metabolism in the rumen epithelium detected by RNA-seq technology.

| Gene_id | Annotation                                                                 | Symbol | In vitro | 24 h | 72 h | 168 h | Post 24 h | Post 168 h |
|---------|----------------------------------------------------------------------------|--------|----------|------|------|-------|-----------|-----------|
| ENSBTAG00000002827 | Acetyl-CoA acetyltransferase 2                                              | ACAT2  | 0.32***  | 0.95 | 0.76 | 0.76  | 1.11      | 1.24      |
| ENSBTAG00000011839 | 3-hydroxy-3-methylglutaryl-CoA synthase 1                                  | HMGCS1| 0.63***  | 0.91 | 0.67 | 0.67  | 1.49      | 1.69      |
| ENSBTAG00000003898 | 3-hydroxy-3-methylglutaryl-CoA synthase 2                                  | HMGCS2| 1.30*    | 0.95 | 0.86 | 0.94  | 0.84      | 0.91      |
| ENSBTAG00000015107 | Monocarboxylate transporter 1                                              | MCT1   | 0.52***  | 0.98 | 0.84 | 0.95  | 0.90      | 0.84      |

*Notes: The number denotes fold changes (treated/control). *FDR $< 0.05$, ***FDR $< 0.001$. 

---

**Figure 4.** A regulatory gene network controlled by FOS. 

**Notes:** The network was inferred using ARACNE at a combined stringent cutoff of an error tolerance $\epsilon = 0.10$ and a $P$-value threshold of mutual information (MI) at $5.0 \times 10^{-11}$. FOS had 4 direct interactions (the first neighbors) and 32 indirect interactions. The expression of all genes in this network at the mRNA level was significantly regulated by butyrate. The green/yellow color with gene symbols represents transcription factors.
HBEGF. HBEGF plays a pivotal role in mediating the early cellular response to intestinal injury by serving as a potent cytoprotective factor.\textsuperscript{45} Other experimental evidence also provides a strong support of a direct interaction between FOS and HBEGF.\textsuperscript{45,46}

Tight junctions between epithelial cells regulate the permeability of molecules via para-cellular pathways as well as bacterial translocation across the gut epithelial layer, thus having the potential to strengthen intestinal barrier function and being involved in intestinal pathology.\textsuperscript{47} In addition to cingulin that was induced by butyrate, at least 16 other tight junction related genes were regulated by butyrate in vitro. A strong up-regulation of the major macromolecular components, such as claudins (CLDN1, CLDN3, CLDN4, CLDN7, CLDN12, and CLDN23), tight junction protein 3 (TJP3), and junctional adhesion molecules 2 and 3 (JAM2 and JAM3), by butyrate supports the contention that these genes may play an important role in maintaining and/or restoring intestinal barrier function. Indeed, evidence indicates that probiotics, such as \textit{Lactobacillus plantarum} MB452, enhance intestinal barrier function via increasing expression of genes encoding proteins involved in tight junction formation.\textsuperscript{48} It is known that elevated ruminal butyrate results in a profound change in the ruminal microbial composition, including a potential stimulating effect on butyrate-producing bacteria.\textsuperscript{12} It is foreseeable that an elevated concentration of butyrate in the lumen of the gut could play a regulatory role in the maintenance of intestinal barrier function via the expression of genes involved in tight junctions. Our future work will include experimental verification of the global regulatory gene networks inferred by computational tools.

**Acknowledgements**

SW and WL were supported by Award R01HG005978 from the National Human Genome Research Institute (NHGRI), Award R01RR025030 from National Center for Research Resources (NCRR), and CAMERA project funded by Gordon and Betty Moore Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHGRI, NCRR or the National Institutes of Health. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture.

**Disclosures and Ethics**

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest.

**References**

1. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. \textit{Physiol Rev.} 1990;70:567–90.
2. Li RW, Li C. Butyrate induces profound changes in gene expression related to multiple signal pathways in bovine kidney epithelial cells. \textit{BMC Genomics.} 2006;7:234. doi:10.1186/1471-2164-7-234.
3. Baldwin RL, Jesse BW. Developmental changes in glucose and butyrate metabolism by isolated sheep ruminal cells. \textit{J Nutr.} 1992;122:1149–53.
4. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. \textit{World J Gastroenterol.} 2011;17:1519–28. doi:10.3748/wjg.v17.i12.1519.
5. Li CJ, Li RW, Wang YH, Elsasser TH. Pathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell line. \textit{Funct Integr Genomics.} 2007;7:193–205. doi:10.1007/s10142-006-0043-2.
6. Li CJ, Li RW. Butyrate induced cell cycle arrest in bovine cells through targeting gene expression relevant to DNA replication apparatus. \textit{Gene Regul Syst Bio.} 2008;2:113–23.
7. Sakata T, Yajima T. Influence of short chain fatty acids on the epithelial cell division of digestive tract. \textit{Q J Exp Physiol.} 1984;69:639–48.

**Author Contributions**

Conceived and designed the experiments: RB, RL. Analysed the data: RB, SW, WL, CL, RL. Wrote the first draft of the manuscript: RB, RL. Contributed to the writing of the manuscript: RB, SW, WL, CL, BB, RL. Agree with manuscript results and conclusions: RB, SW, WL, CL, BB, RL. Jointly developed the structure and arguments for the paper: RB, RL. Made critical revisions and approved final version: RB, SW, WL, CL, BB, RL. All authors reviewed and approved of the final manuscript.
8. Lewis K, Lutgendorff F, Phan V, Soderholm JD, Sherman PM, McKay DM. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis. 2010;16:1138–48. doi:10.1002/ibd.21177.

9. Steele MA, Dionissiopoulos L, AlZahal O, Doelman J, McBride BW. Rumen epithelial adaptation to ruminal acids in lactating cattle involves the coordinated expression of insulin-like growth factor-binding proteins and a cholesterol ester enzyme. J Dairy Sci. 2012;95:318–27. doi:10.3168/jds.2011-4465.

10. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002;217: 133–9.

11. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Enhanced translocation of Illumina second-generation sequencing data. BMC Bioinformatics. 2011;12:35–44. doi:10.1007/s10142-011-0259-7.

12. Li RW, Wu S, Baldwin RLT, Li W, Li C. Perturbation dynamics of the rumen microbiota in response to exogenous butyrate. PLoS One. 2012;7:e29392. doi:10.1371/journal.pone.0029392.

13. Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Oral administration of butyrylubrifosilanes, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J Nutr. 2005;135:2873–88.

14. Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Effect of oral administration of Butyrylubrifosilanes MDT-1, a gastrointestinal bacterium, on 3-methylcholanthrene-induced tumor in mice. Nutr Cancer. 2007;59:92–8. doi:10.1080/01635580701397608.

15. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031–64.

16. Krehbiel CR, Harmon DL, Schneider JE. Effect of increasing ruminal butyrate concentrations of butyrate and butyrate-producing bacteria in feces. J Anim Sci. 1999;123:359–68.

17. Miyauchi S, Gopal E, Fei YJ, Ganapathy V. Functional identification of SLC5AS, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. J Biol Chem. 2004;279:13293–6. doi:10.1074/jbc.C400059200.

18. Li RW, Li C, Elsasser TH, Liu G, Garrett WM, Gasbarre LC. Mucin biosynthesis in the bovine goblet cell induced by Cooperia oncophora infection. Vet Parasitol. 2009;165:281–9. doi:10.1016/j.vetpar.2009.07.008.

19. Li RW, Li C, Gasbarre LC. The vitamin D receptor and inducible nitric oxide synthase associated pathways in acquired resistance to Cooperia oncophora infection in cattle. Vet Res. 2011;42:48. doi:10.1186/1297-9176-42-8.

20. Li RW, Schroder SG. Cytoskeleton remodeling and alterations in smooth muscle contractility in the bovine jejenum during nematode infection. J Cell Sci. 2012;125:34–44. doi:10.1242/jcs.012411-02597.9.

21. Cox MP, Peterson DA, Biggs PJ. Solexa QA. At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics. 2010;11:485. doi:10.1186/1471-2105-11-485.

22. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:110–5. doi:10.1093/bioinformatics/btp120.

23. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511–5. doi:10.1038/nbt.1621.

24. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106. doi:10.1186/gb-2010-11-1-r106.

25. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet. 2005;37:382–90. doi:10.1038/ng1532.

26. Lettau A, Noziere P, Silberberg M, Morgavi DP, Berger C, Martin C. Experimental feed induction of ruminal lactic, propionic, or butyric acidosis in sheep. J Anim Sci. 2010;88:3041–6. doi:10.2527/jas.2010-926.

27. Owens FN, Secrist DS, Hill WJ, Gill DR. Acidosis in cattle: a review. Inflamm Bowel Dis. 2010;88:3041–6. doi:10.1186/1471-2180-10-316.